Volume Alert - M 59.88 Macy's Inc $M Hit a high today of

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - M 59.88 Macy's Inc $M Hit a high today of 60.26 Closing the day 11/07/14 at 59.88 +0.84 +1.42% With a day low of 58.58 and a total volume of 6,480,237.

M Recent Posts: http://investorshangout.com/Macys-Inc-M-51732/

M Macy's Inc Recent Headline News

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.13 (+0.19), KMI: 38.75 (+0.22), HK: 3.24 (+0.34), KSS: 57.22 (+0.41), GE: 26.41 (+0.05), LMT: 186.15 (-3.73), AVAV: 29.81 (-0.65), WMT: 78.77 (+0.96), SNE: 19.62 (-0.08), M: 59.88 (+0.84), SDRL: 21.77 (+0.06), T: 34.91 (+0.19), W: 26.01 (+0.31), OPK: 8.32 (-0.10), QCOM: 69.26 (-1.32), TWTR: 40.31 (-0.53), EPR: 56.61 (+0.23), AAPL: 109.01 (+0.31), HSIC: 128.84 (-1.47), CSCO: 25.33 (+0.07), WFM: 46.81 (+1.96), CY: 10.08 (-0.02), MU: 33.01 (-0.34), SWKS: 59.88 (-2.26), IRM: 38.05 (+1.58), BAC: 17.36 (unch), MO: 49.87 (+0.31), CSX: 35.45 (+0.32), WWAV: 36.93 (-0.53), GILD: 106.45 (-0.49), TXN: 50.90 (unch), BPL: 79.30 (+1.86), JCP: 7.82 (+0.34), JWN: 73.43 (-0.25), BABA: 114.56 (+2.99)

Final Glance: Department Store Retail companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top department store retail companies were mixed at the close of trading:
KSS: 57.22 (+0.41), TJX: 64.00 (-0.56), JWN: 73.43 (-0.25), M: 59.88 (+0.84), SHLD: 42.81 (+10.14)

FTI Consulting's Study Expects 3.5% Jump in Holiday Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:55PM CST
Recent research by FTI Consulting (FCN) projected nominal holiday sales to register a 3.5% increase this season, indicating a healthy pickup from the disappointing holiday performance of 2013.
KSS: 57.22 (+0.41), M: 59.88 (+0.84), SHLD: 42.81 (+10.14), FCN: 40.73 (-0.34)

Macy's (M) Crosses Pivot Point Resistance at $59.68
Comtex SmarTrend(R) - Fri Nov 07, 12:26PM CST
Shares of Macy's (NYSE:M) opened today above their pivot of $58.51 and have already reached the first level of resistance at $59.68. Investors may be interested in a cross of the next upside pivot targets of $60.33 and $62.15.
M: 59.88 (+0.84)

Midday Glance: Department Store Retail companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top department store retail companies are mixed at 1 p.m.:
KSS: 57.22 (+0.41), TJX: 64.00 (-0.56), JWN: 73.43 (-0.25), M: 59.88 (+0.84), SHLD: 42.81 (+10.14)

Sears Mulls REIT To Bring In Cash, Sees Flat Comps
at Investor's Business Daily - Fri Nov 07, 10:02AM CST
Shares of Sears Holdings are surging in morning trading as the struggling department store chain contemplates forming a real estate investment trust (REIT) and selling 200-300 of its own stores to the REIT to raise cash. In an SEC filing, Sears...
M: 59.88 (+0.84), SHLD: 42.81 (+10.14)

Early Glance: Department Store Retail companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top department store retail companies are mixed at 10 a.m.:
KSS: 57.22 (+0.41), TJX: 64.00 (-0.56), JWN: 73.43 (-0.25), M: 59.88 (+0.84), SHLD: 42.81 (+10.14)

Can SodaStream Get Its Pop Back?
Jeremy Bowman, The Motley Fool - Motley Fool - Fri Nov 07, 9:15AM CST
The verdict may be in on SodaStream International , the highly shorted growth stock that peaked near $80 before crashing all the way down to $20 this year. Macy's recently announced it would stop carrying the brand in response to weak sales, a...
KO: 42.32 (+0.03), M: 59.88 (+0.84), SODA: 22.00 (-0.46), PEP: 96.80 (-0.01)

Low Gas Prices May Spur Holiday Spending, But by How Much?
at The Street - Fri Nov 07, 5:10AM CST
The drop in gasoline prices is putting more cash in consumers' pockets, but whether that translates into a big jump in holiday spending remains to be seen.
KSS: 57.22 (+0.41), AMZN: 299.86 (+3.22), WMT: 78.77 (+0.96), M: 59.88 (+0.84)

Q3 Earnings Season Winding Down - Earnings Preview
Sheraz Mian - ZACKS - Fri Nov 07, 1:20AM CST
Q3 Earnings Season Winding Down - Earnings Preview
JWN: 73.43 (-0.25), M: 59.88 (+0.84), WMT: 78.77 (+0.96), CSCO: 25.33 (+0.07)

Lull At The Mall Just Retail's Calm Before Christmas?
at Investor's Business Daily - Thu Nov 06, 5:22PM CST
Shoppers spent less freely in October as they took a break heading into the holiday season's traditional buying frenzy, leading to slow mall traffic and mixed sales reports from retailers Thursday. The jury is still out on how retailers will fare...
ZUMZ: 35.10 (+0.04), M: 59.88 (+0.84), WMT: 78.77 (+0.96), KORS: 69.95 (-2.36), FIVE: 40.73 (+0.75), RAD: 5.41 (+0.06), LB: 75.61 (-0.74), JWN: 73.43 (-0.25), COST: 137.71 (+0.62), GPS: 38.83 (+0.93), KATE: 30.37 (-0.59), AAPL: 109.01 (+0.31), BKE: 49.50 (-0.17), WAG: 66.92 (+0.27), SMRT: 13.72 (-0.05)

Today's Top Performers In Services
at The Street - Thu Nov 06, 11:05AM CST
TheStreet highlights 3 stocks pushing the services sector higher today.
M: 59.88 (+0.84), COST: 137.71 (+0.62), LOW: 57.69 (+0.12)

Apple Pay Will Be a Game Changer But It'll Take Awhile To Get There: Study
at The Street - Thu Nov 06, 9:52AM CST
New research predicts Apple's swipe payment system will be a big success but could take a many years for it to catch on.
AXP: 92.26 (+0.68), WMT: 78.77 (+0.96), M: 59.88 (+0.84), GOOG: 541.01 (-1.03), LUV: 38.24 (+0.30), RAD: 5.41 (+0.06), V: 252.43 (+2.34), EBAY: 53.51 (+0.25), TGT: 64.17 (+2.28), CVS: 88.38 (-0.05), MCD: 95.10 (+0.44), AAPL: 109.01 (+0.31), WAG: 66.92 (+0.27), MA: 84.80 (-0.95)

Upcoming Events and Conferences, Stock Spilt, New Milestone, and Financial Results - Research Reports on Macy's, Vipshop, Southwest Airlines, SYSCO and Canadian Pacific
PR Newswire - Thu Nov 06, 7:45AM CST
Today, Analysts Review released its research reports regarding Macy's, Inc. (NYSE: M), Vipshop Holdings Ltd. (NYSE: VIPS), Southwest Airlines Co. (NYSE: LUV), SYSCO Corporation (NYSE: SYY) and Canadian Pacific Railway Limited (NYSE: CP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7740-100free.
VIPS: 23.34 (-0.04), SYY: 38.14 (+0.15), M: 59.88 (+0.84), CP: 206.47 (+0.78), LUV: 38.24 (+0.30)

Upgrade Alert for Macy's (M)
Comtex SmarTrend(R) - Thu Nov 06, 7:02AM CST
Macy's (NYSE:M) was upgraded from Neutral to Buy at Northcoast today. The stock closed yesterday at $57.19 on volume of 5.0 million shares, above average daily volume of 4.9 million. Macy's (NYSE:M) has potential upside of 12.1% based on a current price of $57.20 and analysts' consensus price target of $64.10. Macy's shares should first meet resistance at the 200-day moving average (MA) of $57.85 and find additional resistance at the 50-day MA of $58.85.
M: 59.88 (+0.84)

3 Holiday Apparel Trends Macy's and J.C. Penney Hope Will Lift Sales
at The Street - Wed Nov 05, 7:32AM CST
Apparel sales at department stores have been off. With the holidays fast approaching, here's Macy's and J.C. Penney say they have plans to reverse the trend.
UA: 66.98 (+0.70), KSS: 57.22 (+0.41), NKE: 93.78 (-0.82), FB: 75.60 (+0.34), VFC: 69.79 (+0.88), JCP: 7.82 (+0.34), M: 59.88 (+0.84), BBY: 35.18 (-0.03), TWTR: 40.31 (-0.53), MSFT: 48.68 (-0.02), AAPL: 109.01 (+0.31)

Macy's Inc (M) Stock Research Links

M Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading